Supporting Information for

A novel self-terminated Prins strategy for the synthesis of tetrahydropyran-4-one derivatives and their behavior in Fisher indole synthesis

B. V. Subba Reddy,*a S. Rehana Anjum, B. Sridharb

^aCentre for Semiochemicals, ^bLaboratory of X-ray Crystallography, CSIR-Indian Institute of Chemical Technology, Hyderabad –500 007, India. E-mail:basireddy@iict.res.in



Table of Contents

 Experimental procedure for Prins cyclization Characterization data of products ¹H and ¹³C NMR spectra of products X-ray crystallography 	
--	--

1. Experimental Section

IR spectra were measured with a Thermo Nicolet Nexus 670 spectrometer . ¹H-NMR spectra were measured with Bruker-400 and Bruker Avance 700 spectrometer. All signals are expressed as ppm downfield from tetramethylsilane used as an internal standard (δ value). ¹³C NMR spectra were recorded on the instruments operating at 75 MHz or 125 MHz with CDCl₃ as a solvent with internal standard (δ 77.0).Mass spectra were taken with Finnigan MAT1020B or JEOL. Column chromatography was performed using E. Merck 100-200, mesh silica gel.

Typical procedure

To a mixture of (3-(phenylthio)but-3-en-1-ol (0.5 mmol) and aldehyde/ketone (0.6 mmol) in anhydrous DCM (5 mL) was added Sc(OTf)₃ (5 mol%) at 0 °C. The resulting mixture was allowed to stir at room temperature for the specified time. After completion of the reaction, the reaction mixture was quenched with water. The organic layer was separated and the aqueous layer was extracted with dichloromethane (2x5 mL). The combined organic phases were washed with brine, dried over anhydrous Na₂SO₄ and concentrated in vacuo. The resulting crude product was purified by silica gel column chromatography (100-200 mesh) using ethyl acetate/hexane gradient mixture to afford the pure product **3**.

2. Characterization data of products

3-(Phenylthio)but-3-en-1-ol (1)



¹H NMR (500 MHz, CDCl₃, δ ppm): 7.41-7.45 (m, 2H), 7.25-7.36 (m, 3H), 5.24 (s, 1H), 5.00 (s, 1H), 3.77 (t, *J* = 6.2 Hz, 2H), 2.48 (t, *J* = 6.0 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃, δ ppm): 142.1, 133.1, 132.4, 129.1, 127.9, 115.0, 60.7, 39.5; I R (neat) v_{max}/cm⁻¹: 3369, 2927, 1609, 1583, 1475, 1439, 1144, 1046, 846, 748, 691; ESI-HRMS calcd for C₁₀H₁₃OS (M+H)⁺ 181.0682, found 181.0684.



¹H NMR (500 MHz, CDCl₃, δ ppm): 7.25-7.29 (m, 3H), 7.19-7.22 (m, 2H), 4.53 (dd, J = 8.5, 5.8 Hz, 1H), 4.32 (ddd, J = 11.6, 7.5, 1.5 Hz, 1H), 3.73 (td, J = 23.8, 2.9 Hz, 1H), 2.57-2.65 (m, 1H), 2.52-2.55 (m, 2H), 2.32 (dt, J = 14.6, 1.4 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃, δ ppm): 206.2, 140.5, 128.6, 128.0, 125.5, 79.7, 66.6, 49.8, 42.1; IR (neat) v_{max}/cm⁻¹: 3419, 2974, 2930, 1721, 1453, 1350, 1254, 1156, 1144, 1057, 755, 699; ESI-HRMS calcd for: C₁₁H₁₃O₂ (M+H)⁺ 177.0910, found 177.0912.

2-(4-Bromophenyl)tetrahydro-4*H*-pyran-4-one (3b):



¹H NMR (500 MHz, CDCl₃, δ ppm): 7.51 (d, *J* = 8.5 Hz, 2H), 7.25 (d, *J* = 8.5 Hz, 2H), 4.61 (dd, *J* = 11.0, 3.0 Hz, 1H), 4.43 (ddd, *J* = 11.6, 7.3, 1.4 Hz, 1H), 3.84 (td, *J* = 23.9, 2.9 Hz, 1H), 2.68-2.76 (m, 1H), 2.54-2.66 (m, 2H), 2.42-2.46 (m, 1H); ¹³C NMR (125 MHz, CDCl₃, δ ppm): 205.7, 139.6, 131.7, 127.2, 121.9, 79.0, 66.7, 49.8, 42.0; IR (neat) v_{max}/cm⁻¹: 3419, 2968, 2858, 1719, 1369, 1247, 1152, 1057, 1025, 756, 699; ESI-HRMS calcd for C₁₁H₁₂BrO₂ (M+H)⁺ 255.0015, found 255.0016.

2-(4-Chlorophenyl)tetrahydro-4H-pyran-4-one (3c):



¹H NMR (500 MHz, CDCl₃, δ ppm): 7.22-7.41 (m, 4H), 4.62 (d, *J*=7.9 Hz, 1H), 4.43 (t, *J*=8.4, Hz, 1H), 3.83 (t, *J*=11.3 Hz, 1H), 2.35-2.82 (m, 4H); ¹³C NMR (125 MHz, CDCl₃, δ ppm): 205.7, 139.0, 133.7, 128.7, 126.9, 78.9, 66.6, 49.8, 42.0; IR (neat) v_{max} /cm⁻¹: 3418, 2863, 2822, 2856, 1719, 1461,

1367, 1367, 1245, 1165,1077, 1029, 778, 700; ESI-HRMS calcd for $C_{11}H_{11}ClO_2$ (M+H)⁺ 211.0526, found 211.03338.

2-(p-Tolyl)dihydro-2H-pyran-4(3H)-one (3d):



¹H NMR (500 MHz, CDCl₃, δ ppm): 7.24 (d, *J*=8.0 Hz, 2H), 7.19 (d, *J*=7.8, Hz, 2H), 4.16 (dd, *J* = 9.1, 4.8 Hz, 1H), 4.42 (ddd, *J* = 11.4, 7.3, 1.5 Hz, 1H), 3.83 (td, *J* = 12.2, 2.8 Hz,1H), 2.67-2.77 (m, 1H), 2.60-2.66 (m, 1H), 2.40-2.44 (m, 1H), 2.35 (s, 3H); ¹³C NMR (125 MHz, CDCl₃, δ ppm): 206.4, 137.6, 129.2, 125.6, 79.7, 66.2, 49.9, 42.1, 21.0; IR (neat) v_{max}/cm⁻¹: 2963, 2922, 2856, 1717, 1367, 1245, 1077, 778, 700; ESI-HRMS calcd for C₁₂H₁₅O₂ (M+H)⁺ 191.1072 found 191.1066.

2-(*m*-Tolyl)tetrahydro-4*H*-pyran-4-one (3e):



¹H NMR (500 MHz, CDCl₃, δ ppm): 7.27 (t, *J* =5.5 Hz, 1H), 7.20 (s, 1H), 7.11-7.18 (m, 2H), 4.61 (dd, *J* = 7.9, 6.2 Hz, 1H), 4.44 (ddd, *J* = 11.5, 7.4, 1.3 Hz, 1H), 3.84 (td, *J* = 11.7, 2.8 Hz, 1H'), 2.59-2.80 (m, 3H), 2.39-2.47 (m, 1H), 2.37 (s, 3H); ¹³C NMR (125 MHz, CDCl₃, δ ppm): 206.4, 140.5, 138.4, 128.9, 128.6, 126.3, 122.7, 79.9, 66.8, 49.9, 42.2, 21.4; IR (neat) v_{max}/cm⁻¹: 3418, 2922, 2856, 1719, 1607, 1367, 1245, 1165, 1077, 778, 700; ESI-HRMS calcd for C₁₂H₁₅O₂ (M+H)⁺ 191.1067 found 191.1068.

2-(4-Isopropylphenyl)dihydro-2*H*-pyran-4(3*H*)-one (3f):



¹H NMR (500 MHz, CDCl₃, δ ppm): 7.29, (d, *J* = 8.1 Hz, 2H), 7.24, (d, *J* = 8.1 Hz, 2H), 4.61 (dd, *J* = 9.9, 4.0 Hz, 1H), 4.41 (dd, *J* = 11.4, 7.3 Hz, 1H), 3.79-3.86 (m, 1H'), 2.91 (sep, *J* = 6.9 Hz, 1H),

2.61-2.75 (m, 3H), 2.42 (d, J = 14.6 Hz, 1H'); ¹³C NMR (125 MHz, CDCl₃, δ ppm): 206.4, 148.9, 137.8, 126.6, 125.7, 79.7, 66.6, 49.7, 42.1, 33.8, 29.6, 23.8; IR (neat) v_{max} /cm⁻¹: 3420, 2961, 2926, 2857, 1720, 1463, 1367, 1248, 1152, 1024, 829. ESI-HRMS calcd for C₁₄H₁₉O₂ (M+H)⁺ 219.1380, found 219.1381.

2-(Naphthalen-2-yl)dihydro-2*H*-pyran-4(3*H*)-one (3g):



¹H NMR (500 MHz, CDCl₃, δ ppm): 8.02 (d, *J* = 8.4 Hz, 1H), 7.89 (dd, *J* = 7.9, 1.5 Hz, 1H), 7.83 (d, *J* = 8.2 Hz, 1H), 7.66 (d, *J* = 7.2 Hz, 1H), 7.55 (dd, *J* = 8.2, 1.5 Hz, 1H), 7.50 (d, *J* = 7.2 Hz, 1H), 5.40 (dd, *J* = 10.2, 3.8 Hz, 1H), 4.50 (ddd, *J* = 11.7, 7.3, 2.0 Hz, 1H), 4.00 (td, *J* = 23.5, 3.0 Hz, 1H), 2.78-2.90 (m, 3H), 2.51-2.56 (m, 1H); ¹³C NMR (125 MHz, CDCl₃, δ ppm): 206.6, 135.9, 133.7, 129.9, 128.9, 128.7, 126.3, 125.7, 125.4, 123.1, 122.8, 76.9, 66.7, 49.1, 42.3; IR (neat) v_{max}/cm⁻¹: 3398, 2891, 1701, 1594, 1255, 1063, 1008, 793, 773. ESI-HRMS calcd for C₁₅H₁₅O₂ (M+H)⁺ 227.1066, found 227.1070.

(E)-2-Styryldihydro-2H-pyran-4(3H)-one (3h):



¹H NMR (500 MHz, CDCl₃, δ ppm): 7.39 (dd, J = 8.7, 1.5 Hz, 2H), 7.33 (t, J = 7.5 Hz, 2H), 7.24-7.28 (m, 1H), 6.65 (d, J = 16.0 Hz, 1H), 6.23 (dd, J = 16.0, 5.9 Hz, 1H), 4.37 (ddd, J = 11.4, 7.2, 1.7 Hz, 1H), 4.29-4.34 (m, 1H), 3.79 (td, J = 23.6, 3.0 Hz, 1H), 2.62-2.69 (m, 1H), 2.50-2.59 (m, 2H), 2.37-2.43 (m, 1H'); ¹³C NMR (125 MHz, CDCl₃, δ ppm): 206.1, 136.0, 131.6, 128.5, 127.9, 126.5, 78.1, 66.3, 48.1, 42.1; IR (neat) ν_{max}/cm^{-1} : 3420, 3026, 2962, 2921, 2852, 1718, 1366, 1246, 1079, 749. ESI-HRMS calcd for: C₁₃H₁₃O₂ (M-H)⁺ 201.0908 found 201.0910.

2-(4-Methoxyphenyl)dihydro-2H-pyran-4(3H)-one (3i)



¹H NMR (500 MHz, CDCl₃, δ ppm): 7.25-7.34 (m, 2H), 6.91 (d, *J* = 9.0 Hz, 2H), 4.60 (dd, *J* = 9.8,4.5 Hz, 1H), 4.35-4.45 (m, 1H), 3.77-3.88 (m, 4H), 2.60-2.79 (m, 3H), 2.38-2.47 (m, 1H); ¹³C NMR (125 MHz, CDCl₃, δ ppm): 206.5, 159.4, 137.0, 132.7, 127.0, 114.0, 79.5, 66.7, 55.3, 49.9, 42.1. IR (neat) v_{max}/cm⁻¹: 2984, 2881, 1740, 1594, 1378, 1255, 773; ESI-HRMS calcd for C₁₂H₁₅O₃ (M+H)⁺ 207.1021, found 207.1013.

2-(3,4,5-Trimethoxyphenyl)dihydro-2*H*-pyran-4(3*H*)-one (3j):



¹H NMR (500 MHz, CDCl₃, δ ppm): 6.60 (s, 2H), 4.59 (t, *J* = 7.0 Hz, 1H), 4.44 (dd, *J* = 11.6, 7.5 Hz, 1H), 3.88 (s, 6H), 3.84 (s, 3H), 3.84 (td, *J*= 23.8, 2.9 Hz, 1H), 2.70-2.77 (m, 1H), 2.65 (d, *J* = 7.3 Hz, 1H), 2.44 (d, *J* = 14.6 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃, δ ppm): 206.1, 153.4, 137.7, 136.1, 102.6, 79.9, 66.7, 60.8, 56.1, 50.0, 42.0. IR (neat) v_{max}/cm⁻¹: 3389, 2947, 2857, 1714, 1524, 1460, 1369, 1234, 1129, 1061, 708. ESI-HRMS calcd for C₁₄H₁₉O₅ (M+H)⁺ 267.1227, found 267.1228.

2-(4-(Benzyloxy)-3-methoxyphenyl)dihydro-2H-pyran-4(3H)-one (3k):



¹H NMR (500 MHz, CDCl₃, δ ppm): 7.25-7.47 (m, 5H), 6.96 (s, 1H), 6.83 (dd, J = 18.1, 8.3 Hz, 2H), 5.15 (s, 2H), 4.57 (dd, J = 9.0, 5.3 Hz, 1H), 4.40 (dd, J = 11.3, 7.5 Hz, 1H), 3.91 (s, 3H), 3.81 (td, J = 24.2, 2.3 Hz, 1H), 2.59-2.77 (m, 3H), 2.41 (d, J = 14.3 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃, δ ppm): 206.4, 149.8, 148.0, 137.0, 133.7, 128.5, 127.8, 127.2, 118.0, 114.0, 109.5, 79.6, 71.0, 66.3,

56.0, 49.9, 42.1; IR (neat) v_{max} /cm⁻¹: 3420, 2961, 2926, 2857, 1720, 1463, 1367, 1248, 1152, 1086, 1024, 829. ESI-HRMS calcd for C₁₉H₂₁O₄ (M+H)⁺ 313.1434, found 313.1435.

2-Butyltetrahydro-4*H*-pyran-4-one (3l)



¹H NMR (500 MHz, CDCl₃, δ ppm): 4.29 (dd, J = 11.4, 7.3 Hz, 1H), 3.65 (td, J = 11.6, 2.9 Hz, 1H), 3.54-3.60(m, 1H), 2.54-2.64 (m, 1H), 2.40 (d, J = 14.3 Hz, 1H), 2.25-2.35 (m, 2H), 1.61-1.72 (m,1H), 1.29-1.58 (m, 6H), 0.91 (t, J = 7.2 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃, δ ppm): 207.3, 78.0,66.4, 48.3, 42.2, 36.0, 27.2, 22.5, 13.9; IR (neat) v_{max}/cm⁻¹: 3444, 2956, 2926, 1716, 1584, 1464, 1361, 1150, 739, 691; ESI-HRMS calcd for C₉H₁₅O₂ (M-H)⁺ 155.1066, found 155.1065.

2-Isobutyldihydro-2*H*-pyran-4(3*H*)-one (3m)



¹H NMR (500 MHz, CDCl₃, δ ppm): 4.29 (ddd, J = 11.5, 7.5, 1.3 Hz, 1H), 3.59-3.72 (m, 2H), 2.52-2.66(m, 1H), 2.16-2.43 (m, 3H), 1.73-1.90 (m,1H), 1.57-1.70 (m, 1H), 1.20-1.35 (m, 1H), 0.92 (dd, J = 6.6, 5.8 Hz, 6H); ¹³C NMR (125 MHz, CDCl₃, δ ppm): 207.1, 76.3, 66.5, 48.8, 45.4, 42.2, 24.2, 23.0, 22.1; IR (neat) v_{max} /cm⁻¹: 3425, 2958, 2928, 2868, 1721, 1468, 1376, 1250, 1161, 1087, 769; ESI HRMS calcd for C₉H₁₇O₂ (M-H)⁺ 157.1224, found 157.12234.

2-Pentyldihydro-2*H*-pyran-4(3*H*)-one (3n):



¹H NMR (500 MHz, CDCl₃, δ ppm): 4.26 (ddd, J = 11.6, 7.5, 1.4 Hz, 1H), 3.63 (td, J = 23.8, 2.9 Hz, 1H), 3.52-3.57 (m, 1H), 2.52-2.60 (m, 1H), 2.37 (dt, J = 14.3, 2.4 Hz, 1H), 2.23-2.32 (m, 2H), 1.60-1.67 (m, 1H), 1.38-1.52 (m, 2H), 1.22-1.35 (m, 6H), 0.87 (t, J = 7.0 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃, δ ppm): 207.1, 78.1, 66.4, 48.3, 42.2, 36.2, 31.6, 24.7, 22.4, 13.9; IR (neat) v_{max} /cm⁻¹: 3422,

2929, 2857, 1718, 1463, 1378, 1219, 1087, 770. ESI-HRMS calcd for $C_{10}H_{19}O_2$ (M+H)⁺ 171.1379, found 171.1382.

2-(4-hydroxyphenyl)dihydro-2H-pyran-4(3H)-one (3o):



¹H NMR (500 MHz, CDCl₃, δ ppm): 7.24 (d, *J* = 8.3 Hz, 2H), 6.83 (d, *J* = 8.5 Hz, 2H), 5.48 (br s, 1H, -OH), 4.59 (dd, *J* = 9.6, 4.3 Hz, 1H), 4.40 (dd, *J* = 11.5, 7.4 Hz, 1H), 3.83 (td, *J* = 23.8, 3.0 Hz, 1H), 2.58-2.78 (m, 3H), 2.43 (dt, *J* = 14.5, 1.1 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃, δ ppm): 207.0, 155.7, 132.5, 127.3, 115.4, 79.5, 66.5, 49.7, 42.1; IR (neat) v_{max}/cm⁻¹: 3241, 2925, 2855, 1698, 1517, 1460, 1367, 1263, 1150, 823. ESI-HRMS calcd for C₁₁H₁₃O₃ (M+H)⁺ 193.0859, found 193.0862.

2-(Furan-2-yl)dihydro-2*H*-pyran-4(3*H*)-one (3p):



¹H NMR (500 MHz, CDCl₃, δ ppm): 7.43 (dd, J = 1.9, 0.9 Hz, 1H), 6.36 (dd, J = 3.2, 1.7 Hz, 1H), 6.33 (dt, J = 3.4, 0.7 Hz, 1H), 4.82 (dd, J = 10.0, 3.8 Hz, 1H), 4.19-4.27 (m, 1H), 3.81-3.90 (m, 1H), 2.88 (ddd, J = 14.7, 9.8, 1.1 Hz, 1H), 2.59-2.73 (m, 2H), 2.42-2.50 (m, 1H) ; ¹³C NMR (125 MHz, CDCl₃, δ ppm): 205.5, 152.1, 142.9, 110.2, 108.2, 72.2, 65.5, 45.3, 42.0; IR (neat) v_{max}/cm^{-1} : 3121, 2925, 2854, 1725, 1462, 1261, 1078, 1018, 800. ESI-HRMS calcd for: C₉H₁₁O₃ (M+H)⁺ 167.0703, found 167.0705

1-Oxaspiro[5.5]undecan-4-one (3q):



¹H NMR (500 MHz, CDCl₃, δ ppm): 3.92-3.98 (m, 2H), 2.37-2.42 (m, 2H), 2.30 (s, 2H), 1.68-1.77 (m,2H), 1.48-1.62 (m, 3H), 1.16-1.45 (m, 5H); ¹³C NMR (125 MHz, CDCl₃, δ ppm): 207.6, 76.6,

59.8, 52.9, 41.7, 35.0, 25.2, 21.1; IR (neat) v_{max} /cm⁻¹: 3419, 2931, 2858, 1718, 1446, 1374, 13.8, 1263, 1075, 962, 746; ESI HRMS calcd for $C_{10}H_{17}O_2$ (M-H)⁺ 169.1223, found 167.10661

Experimental procedure for the Fischer indole product

Phenylhydrazine hydrochloride (0.25 g, 1.62 mmol) and 2-substituted tetrahydropyran-4-one (, 0.14g, 1.62 mmol) were added to glacial acetic acid (2 g, 0.03 mol) and the mixture was refluxed for 6h with stirring. The mixture was then cooled and neutralized with 1 M NaOH, then diluted with water (100 mL) and extracted with CHCl₃ (3×100 mL). Following the drying of the organic layer over Na₂SO₄, the solvent was removed under vacuum and the residue was passed through a short plug of silica gel to afford the pure product.

1-(1-Phenyl-3,4-dihydropyrano[4,3-b]indol-5(1*H*)-yl)ethanone 7a (major):



¹H NMR (500 MHz, CDCl₃, δ ppm): 7.24-7.37 (m, 7H), 7.13-7.16 (m, 2H), 6.38 (s, 1H), 4.42 (t, *J* = 6.8 Hz, 2H), 3.07 (t, *J* = 7.0 Hz, 2H), 2.09 (s, 3H); ¹³C NMR (125 MHz, CDCl₃, δ ppm): 171.1, 149.8, 143.8, 139.9, 130.5, 128.6, 128.4, 128.1, 127.2, 125.1, 107.0, 63.7, 29.6, 27.8. ppm; IR (neat) v_{max}/cm⁻¹: 3449, 3059, 2925, 2854, 1738,1597, 1502, 1239, 1035, 764, 696; HRMS (ESI) calcd for C₁₉H₁₇NO₂: 291.1259 found : 291.1141.

2-(1,5-Diphenyl-4,5-dihydro-1H-pyrazol-3-yl)ethanol 8a (minor):



¹H NMR (500 MHz, CDCl₃, δ ppm): 7.23-7.36 (m, 5H), 7.14 (t, *J* = 7.1 Hz, 2H), 6.91 (d, *J* = 7.9 Hz, 2H), 6.76 (t, *J* = 7.3 Hz, 1H), 5.01 (dd, *J* =11.5, 8.5 Hz, 1H), 3.99 (t, *J* = 5.6 Hz, 2H), 3.45 (dd, *J* = 17.5, 12.0 Hz, 1H), 2.77 (dd, *J* =17.5, 8.2 Hz, 1H), 2.57 (t, *J* = 5.4 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃, δ ppm): 150.4, 145.7, 142.6, 129.0, 128.9, 127.5, 125.9, 118.9, 113.1, 64.2, 59.7, 47.1, 32.8 ppm; IR (neat) v_{max}/cm⁻¹: 3386, 2925, 1598, 1499, 1050, 751, 697; HRMS (ESI) calcd for C₁₇H₁₉ON₂ = 267.1491. found : 267.1483.

1-(1-Phenyl-3,4-dihydropyrano[4,3-b]indol-5(1*H*)-yl)ethanone 7c (major):



¹H NMR (500 MHz, CDCl₃, δ ppm): 7.25-7.35 (m, 7H), 7.22 (dd, *J* =5.4, 2.1 Hz, 1H), 6.38 (s, 1H), 4.43 (t, *J* = 7.0 Hz, 2H), 3.08 (t, *J* = 7.0 Hz, 2H), 2.09 (s, 3H); ¹³C NMR (125 MHz, CDCl₃, δ ppm): 171.1, 149.9, 142.5, 139.7, 134.2, 129.8, 129.0, 128.7, 127.5, 125.1, 107.1, 63.6, 27.8, 21.1 ppm; IR (neat) v_{max}/cm⁻¹: 3420, 2907, 1702, 1597, 1500, 1323, 1163, 1091, 1063, 820, 743, 691 cm⁻¹; HRMS (ESI) calcd for C₁₉H₁₅CINO₂: 324.0797 found : 324.1431.

2-(1,5-Diphenyl-4,5-dihydro-1*H*-pyrazol-3-yl)ethanol 8c (minor):



¹H NMR (500 MHz, CDCl₃, δ ppm): 7.31 (d, *J* = 8.5 Hz, 2H), 7.24 (d, *J* = 8.5 Hz, 2H), 7.15 (td, d, *J* = 14.3, 1.9 Hz, 2H) 6.88 (dd, *J* = 8.8, 1.0 Hz, 2H), 6.78 (t, *J* = 7.3 Hz, 1H), 4.99 (dd, *J* = 11.9, 8.2 Hz, 1H), 3.99 (dd, *J* = 10.6, 5.3 Hz, 2H), 3.46 (dd, *J* = 17.5, 12.0 Hz, 1H), 2.74 (dd, *J* = 17.5, 8.2 Hz, 1H), 2.58 (t, *J* = 5.4 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃, δ ppm): 150.4, 145.5, 141.1, 133.2, 129.2, 128.9, 127.3 119.3, 113.9, 63.6, 59.7, 47.0, 32.8 ppm; IR (neat) v_{max}/cm⁻¹: 3450, 2927, 1602, 1462, 1429, 1366, 1153, 1034, 789. HRMS (ESI) calcd for C₁₇H₁₈ON₂Cl : 301.1108 found : 301.1101.

3. ¹H and ¹³C NMR spectra of products



¹H NMR spectrum of compound 1



 ^{13}C NMR spectrum of compound 1



¹H NMR spectrum of compound **3a**



¹³C NMR spectrum of compound **3a**



 $^1\mathrm{H}$ NMR spectrum of compound $\mathbf{3b}$



¹³C NMR spectrum of compound **3b**



¹H NMR spectrum of compound 3c



¹³C NMR spectrum of compound **3**c







¹³C NMR spectrum of compound **3d**



¹H NMR spectrum of compound 3e



¹³C NMR spectrum of compound **3e**



¹H NMR spectrum of compound **3f**



 $^{13}\mathrm{C}$ NMR spectrum of compound 3f







 $^{13}\mathrm{C}$ NMR spectrum of compound 3g



 $^1\mathrm{H}$ NMR spectrum of compound $\mathbf{3h}$



 $^{13}\mathrm{C}$ NMR spectrum of compound 3h



¹H NMR spectrum of compound **3i**



¹³C NMR spectrum of compound **3i**



¹H NMR spectrum of compound 3j



¹³C NMR spectrum of compound **3**j



 $^1\mathrm{H}$ NMR spectrum of compound 3k



 ^{13}C NMR spectrum of compound 3k



¹H NMR spectrum of compound **3**l



¹³C NMR spectrum of compound **3**l



¹H NMR spectrum of compound **3m**



¹³C NMR spectrum of compound **3m**



¹H NMR spectrum of compound **3n**



¹³C NMR spectrum of compound **3n**



¹H NMR spectrum of compound 30



¹³C NMR spectrum of compound **30**



¹H NMR spectrum of compound **3p**



¹³C NMR spectrum of compound **3p**



¹H NMR spectrum of compound 3q



 $^{13}\mathrm{C}$ NMR spectrum of compound $\mathbf{3q}$



¹H NMR spectrum of compound **7a (major)**



¹³C NMR spectrum of compound **7a (major)**



¹H NMR spectrum of compound **8a (minor)**



¹³C NMR spectrum of compound 8a (minor)



¹H NMR spectrum of compound **7c (major)**



¹³C NMR spectrum of compound **7c (major)**



¹H NMR spectrum of compound **8c (minor)**



¹³C NMR spectrum of compound **8c (minor)**

4. X-ray Crystallography

X-ray data for the compounds were collected at room temperature using a Bruker Smart Apex CCD diffractometer with graphite monochromated MoK α radiation (λ =0.71073Å) with ω -scan method [1]. Preliminary lattice parameters and orientation matrices were obtained from four sets of frames.

Integration and scaling of intensity data was accomplished using SAINT program [1]. The structure was solved by direct methods using SHELXS [2] and refinement was carried out by full-matrix least-squares technique using SHELXL [2]. Anisotropic displacement parameters were included for all non-hydrogen atoms. O- bound and C-bound H atoms were located in a difference density map but were positioned geometrically and included as riding atoms, with O-H distance = 0.82 Å and C—H distance = 0.93 - 0.97 Å and with $U_{iso}(H) = 1.5U_{eq}(C \text{ and } O)$ and $1.2U_{eq}(C)$ for the other H atoms. The methyl groups were allowed to rotate but not to tip. Owing to the poor quality and diffraction ability of the crystal, the data set contains a large number of weak high-angle reflections, which accounts for the high K values in the analysis of variance. Hence, the SHEL command was used to cut off the weak high-angle reflections.

Crystal Data for 8c: $C_{17}H_{17}N_2OC1$ (M=300.79): triclinic, space group P-1 (no. 2), a = 5.479(3) Å, b = 7.926(4) Å, c = 18.296(9) Å, $a = 78.658(8)^\circ$, $\beta = 86.196(8)^\circ$, $\gamma = 79.757(8)^\circ$, V = 766.2(6) Å³, Z = 2, T = 294.15 K, μ (MoK α) = 0.250 mm⁻¹, *Dcalc* = 1.3036 g/mm³, 8327 reflections measured ($4.54 \le 2\Theta \le 56.66$), 3488 unique ($R_{int} = 0.0934$) which were used in all calculations. The final R_1 was 0.1306 (I>2 σ (I)) and wR_2 was 0.2288 (all data). CCDC 1440304 contains supplementary Crystallographic data for the structure. These data can be obtained free of charge at www.ccdc.cam.ac.uk/conts/retrieving.html [or from the Cambridge Crystallographic Data Centre (CCDC), 12 Union Road, Cambridge CB2 1EZ, UK; fax: +44(0) 1223 336 033; email: deposit@ccdc.cam.ac.uk].

- Bruker (2001). SAINT (Version 6.28a) & SMART (Version 5.625). Bruker AXS Inc., Madison, Wisconsin, USA.
- 2. Sheldrick G. M. (2015) Acta Crystallogr C71: 3-8.